WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD.

Wanbangde Pharmaceutical Holding Group Co., Ltd.

002082

CNE000001P94

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
5.11 ^CNY	-0.58%		-3.77%	-20.16%

05-08	US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A	MT
04-29	Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Cash Dividend for the Year 2022

May 17, 2023 at 08:56 pm

Wanbangde Pharmaceutical Holding Group Co., Ltd. approved Cash dividend/10 shares (tax included): CNY 1.20000000 for the year 2022, at its Annual General Meeting of 2022 on 16 May 2023.

Latest news about Wanbangde Pharmaceutical Holding Group Co., Ltd.

US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A	05-08	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-26	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Wanbangde Pharma Elects Vice Chairman, Appoints CFO	01-29	MT
Wanbangde Pharma's Anesthesia Passes Drug Regulator's Consistency Evaluation	01-19	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) added to S&P Global BMI Index	18/09/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Board Appointments	31/07/23	CI
Wanbangde Pharmaceutical Registers New Medical Device	10/07/23	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 05 June 2023	30/05/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Cash Dividend for the Year 2022	17/05/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Profit Distribution Proposal for 2022	26/04/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) dropped from S&P Global BMI Index	19/12/22	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI
Wanbangde Pharma in Talks to Buy Controlling Stake in Consun Pharma	26/07/22	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	13/04/22	CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.	14/03/22	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback announced on March 15, 2021, has expired with 5,000,000 shares, representing 0.81% for CNY 59.98 million.	12/03/22	CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.	03/01/22	CI

Chart Wanbangde Pharmaceutical Holding Group Co., Ltd.

Duration

Period

Chart Wanbangde Pharmaceutical Holding Group Co., Ltd.

More charts

Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

06:30am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD.	-20.16%	436M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.59%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+18.22%	15.33B
CIPLA LIMITED	+12.26%	13.74B
ZYDUS LIFESCIENCES LIMITED	+52.55%	12.16B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.88%	5.66B